



November 2, 2006

## **Peregrine Pharmaceuticals to Present at Rodman & Renshaw 8th Annual Healthcare Conference**

- Presentation to Be Webcast Live and Archived on Company's Website -

TUSTIN, Calif., Nov. 2 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company developing targeted therapeutics for the treatment of hepatitis C virus (HCV) infection and cancer, today announced that senior management will present at the Rodman & Renshaw 8th Annual Healthcare Conference on Wednesday, November 8, 2006 at 9:55 am EST. The presentation will be held at the New York Palace Hotel in New York City.

Peregrine CEO and president Steven W. King will provide a review of recent corporate developments.

Mr. King's presentation will be webcast live and can be accessed by visiting the Investor Relations section of Peregrine's website at [www.peregrineinc.com](http://www.peregrineinc.com). A replay will be available on the Peregrine website and archived for approximately 30 days.

For more information about this conference, please visit: <http://www.rodmanandrenshaw.com/Conferences.asp?CID=conf19>

### About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing five separate clinical trials in cancer and HCV infection with its lead product candidates bavituximab and Cotara®; in the U.S. and India. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. ([www.avidbio.com](http://www.avidbio.com)), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at [www.peregrineinc.com](http://www.peregrineinc.com).

#### Contacts:

GendeLLindheim BioCom Partners

Investors

[info@peregrineinc.com](mailto:info@peregrineinc.com)

(800) 987-8256

Media

Barbara Lindheim

(212) 918-4650

SOURCE Peregrine Pharmaceuticals, Inc.

11/02/2006

CONTACT: Investors, +1-800-987-8256, [info@peregrineinc.com](mailto:info@peregrineinc.com), or Media, Barbara Lindheim, +1-212-918-4650, both of GendeLLindheim BioCom Partners, for Peregrine Pharmaceuticals, Inc.

Web site: <http://www.avidbio.com>

Web site: <http://www.peregrineinc.com>

(PPHM)